TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06382675: Clinical Performance of the New Plasma Filter PX2 in Combination With the multiFiltrate and multiFiltratePRO in TPE Treatments

Sponsor: Fresenius Medical Care Deutschland GmbH · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 46 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,865,500

Rescue Site Savings

+$4,519,500

Unlock Full NCT06382675 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06382675 Rescue Dossier →